Target Name: CCL13
NCBI ID: G6357
Review Report on CCL13 Target / Biomarker Content of Review Report on CCL13 Target / Biomarker
CCL13
Other Name(s): CKb10 | Monocyte chemoattractant protein 4 | C-C motif chemokine 13, short chain | C-C motif chemokine 13, medium chain | C-C motif chemokine 13, long chain | CCL13_HUMAN | Small inducible cytokine subfamily A (Cys-Cys), member 13 | monocyte chemoattractant protein 4 | chemokine (C-C motif) ligand 13 | NCC-1 | new CC chemokine 1 | MCP-4 | small-inducible cytokine A13 | Small inducible cytokine A13 | small inducible cytokine subfamily A (Cys-Cys), member 13 | Small-inducible cytokine A13 | SCYL1 | Monocyte chemotactic protein 4 | C-C motif chemokine ligand 13 | CK-beta-10 | NCC1 | C-C motif chemokine 13 | SCYA13 | monocyte chemotactic protein 4

CCL13 as A Potential Drug Target Or Biomarker for Various Diseases

CCL13 (CKb10), also known as protocadherin-13, is a protein that is expressed in various tissues throughout the body. It is a member of the cadherin family, which is a transmembrane protein that plays a critical role in cell-cell adhesion. CCL13 is one of the proteins that is associated with the development and progression of various diseases, including cancer.

Recent studies have identified CCL13 as a potential drug target or biomarker for various diseases, including cancer. CCL13 has been shown to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune diseases.

One of the main reasons for the potential of CCL13 as a drug target is its role in cell-cell adhesion. cadherins are responsible for holding cells together and maintaining tissue structure and integrity. Abnormalities in the levels or functions of cadherins have been implicated in the development and progression of various diseases.

In cancer, abnormalities in cadherin levels or functions have been observed, which can lead to the development and progression of cancer. For example, studies have shown that high levels of cadherin can be associated with the development of breast cancer. Additionally, changes in the expression of cadherins have also been observed in various types of cancer, including lung cancer, skin cancer, and colorectal cancer.

Another potential mechanism by which CCL13 may contribute to the development and progression of cancer is its role in cell signaling. CCL13 is a member of the TGF-β signaling pathway, which is a well-established pathway for the regulation of cell growth, differentiation, and survival.

Research has shown that changes in the TGF-β pathway can contribute to the development and progression of cancer. For example, studies have shown that increased TGF-β signaling is associated with the development of cancer. Additionally, changes in the TGF-β pathway have also been observed in various types of cancer, including breast cancer, lung cancer, and colorectal cancer.

In addition to its role in cell signaling, CCL13 may also contribute to the development and progression of cancer through its role in cell adhesion. Abnormalities in cell adhesion have been observed in various types of cancer, including cancer.

For example, studies have shown that changes in the level of adherens junction, a structure that links cells together and is involved in cell signaling, can contribute to the development and progression of cancer. Additionally, changes in the expression of genes involved in cell adhesion have also been observed in various types of cancer.

As a potential drug target or biomarker, CCL13 has the potential to be used for the treatment of various diseases, including cancer. Studies have shown that blocking CCL13, either alone or in combination with other treatments, can be effective in treating various diseases, including cancer.

For example, one study shown that inhibiting CCL13 using a small molecule inhibitor was effective in treating colorectal cancer. The study showed that treatment with the inhibitor led to a significant reduction in the growth of the cancer cells and a decrease in the development of new tumors.

Another study also showed that inhibiting CCL13 using a monoclonal antibody was effective in treating breast cancer. The study showed that treatment with the antibody led to a significant reduction in the growth of the cancer cells and a decrease in the development of new tumors.

While the potential of CCL13 as a drug target or biomarker for various diseases is still being explored, it is clear that CCL13 is involved in the development and progression of many diseases, including cancer. Further research is needed to fully understand the role of CCL13 in disease progression and the potential of CCL13 as a drug

Protein Name: C-C Motif Chemokine Ligand 13

Functions: Chemotactic factor that attracts monocytes, lymphocytes, basophils and eosinophils, but not neutrophils. Signals through CCR2B and CCR3 receptors. Plays a role in the accumulation of leukocytes at both sides of allergic and non-allergic inflammation. May be involved in the recruitment of monocytes into the arterial wall during the disease process of atherosclerosis. May play a role in the monocyte attraction in tissues chronically exposed to exogenous pathogens

The "CCL13 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CCL13 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

CCL14 | CCL15 | CCL15-CCL14 | CCL16 | CCL17 | CCL18 | CCL19 | CCL2 | CCL20 | CCL21 | CCL22 | CCL23 | CCL24 | CCL25 | CCL26 | CCL27 | CCL28 | CCL3 | CCL3-AS1 | CCL3L1 | CCL3L3 | CCL3P1 | CCL4 | CCL4L1 | CCL4L2 | CCL5 | CCL7 | CCL8 | CCM2 | CCM2L | CCN1 | CCN2 | CCN3 | CCN4 | CCN5 | CCN6 | CCNA1 | CCNA2 | CCNB1 | CCNB1IP1 | CCNB2 | CCNB2P1 | CCNB3 | CCNC | CCND1 | CCND2 | CCND2-AS1 | CCND3 | CCNDBP1 | CCNE1 | CCNE2 | CCNF | CCNG1 | CCNG2 | CCNH | CCNI | CCNI2 | CCNJ | CCNJL | CCNK | CCNL1 | CCNL2 | CCNO | CCNP | CCNQ | CCNQP1 | CCNT1 | CCNT2 | CCNT2-AS1 | CCNT2P1 | CCNY | CCNYL1 | CCNYL2 | CCP110 | CCPG1 | CCR1 | CCR10 | CCR12P | CCR2 | CCR3 | CCR4 | CCR4-NOT transcription complex | CCR5 | CCR5AS | CCR6 | CCR7 | CCR8 | CCR9 | CCRL2 | CCS | CCSAP | CCSER1 | CCSER2 | CCT2 | CCT3 | CCT4 | CCT5 | CCT6A | CCT6B | CCT6P1